{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:13:00Z","timestamp":1780445580470,"version":"3.54.1"},"reference-count":17,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2010,4,1]],"date-time":"2010-04-01T00:00:00Z","timestamp":1270080000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Regulatory Toxicology and Pharmacology"],"published-print":{"date-parts":[[2010,4]]},"DOI":"10.1016\/j.yrtph.2009.11.006","type":"journal-article","created":{"date-parts":[[2009,11,24]],"date-time":"2009-11-24T09:57:23Z","timestamp":1259056643000},"page":"247-275","source":"Crossref","is-referenced-by-count":31,"title":["Prediction of drug-related cardiac adverse effects in humans\u2014A: Creation of a database of effects and identification of factors affecting their occurrence"],"prefix":"10.1016","volume":"56","author":[{"given":"Edwin J.","family":"Matthews","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna A.","family":"Frid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.yrtph.2009.11.006_bib1","doi-asserted-by":"crossref","first-page":"875","DOI":"10.2165\/00002018-200629100-00005","article-title":"Comparative performance of two quantitative safety signaling methods","volume":"29","author":"Almenoff","year":"2006","journal-title":"Drug Safety"},{"key":"10.1016\/j.yrtph.2009.11.006_bib2","series-title":"Computational Toxicology. Risk Assessment for Pharmaceuticals and Environmental Chemicals","first-page":"3","author":"Combs","year":"2006"},{"key":"10.1016\/j.yrtph.2009.11.006_bib3","series-title":"Introduction to Biochemical Toxicity","first-page":"673","article-title":"Cardiovascular toxicity","author":"Combs","year":"2001"},{"key":"10.1016\/j.yrtph.2009.11.006_bib4","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/bjc.1979.10","article-title":"Describing the validity of carcinogen screening tests","volume":"39","author":"Cooper","year":"1979","journal-title":"Brit. J. Cancer"},{"key":"10.1016\/j.yrtph.2009.11.006_bib5","unstructured":"COSTART. Coding Symbols for Thesaurus of Adverse Reaction Terms, 5th ed., Department of Health and Human Services: Rockville, MD, 1995."},{"key":"10.1016\/j.yrtph.2009.11.006_bib6","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/0092-8674(95)90358-5","article-title":"A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome","volume":"80","author":"Curren","year":"1995","journal-title":"Cell"},{"key":"10.1016\/j.yrtph.2009.11.006_bib7","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/pds.677","article-title":"Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports","volume":"10","author":"Evans","year":"2001","journal-title":"Pharmacoepidemiol. Drug Safety"},{"key":"10.1016\/j.yrtph.2009.11.006_bib8","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.yrtph.2009.11.005","article-title":"Prediction of drug-related cardiac adverse effects in humans\u2014B: Use of QSAR systems for early detection of drug-induced cardiac toxicities","volume":"56","author":"Frid","year":"2010","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.yrtph.2009.11.006_bib9","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1177\/009286150103500134","article-title":"Evaluation of the characteristics of safety withdrawal of prescription drugs from worldwide pharmaceutical markets-1960 to 1999","volume":"25","author":"Fung","year":"2001","journal-title":"Drug Inform. J."},{"key":"10.1016\/j.yrtph.2009.11.006_bib10","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1006\/rtph.1998.1259","article-title":"A new highly specific method for predicting the carcinogenic potential of pharmaceuticals in rodents using enhanced MCASE QSAR-ES software","volume":"28","author":"Matthews","year":"1998","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.yrtph.2009.11.006_bib11","doi-asserted-by":"crossref","first-page":"243","DOI":"10.2174\/1570163043334794","article-title":"Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling","volume":"I","author":"Matthews","year":"2004","journal-title":"Curr. Drug Discov. Technol."},{"key":"10.1016\/j.yrtph.2009.11.006_bib12","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1517\/17425255.3.1.125","article-title":"In silico approaches to explore toxicity end points: issues and concerns for estimating human health effects","volume":"3","author":"Matthews","year":"2007","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.yrtph.2009.11.006_bib13","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.yrtph.2009.01.007","article-title":"Identification of structure activity relationships for adverse effects of pharmaceuticals in humans: C. Use of QSAR and an expert system for the estimation of the mechanism of action of drug-induced hepatobiliary and urinary tract toxicities","volume":"54","author":"Matthews","year":"2009","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.yrtph.2009.11.006_bib14","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.yrtph.2009.01.009","article-title":"Identification of structure\u2013activity relationships for adverse effects of pharmaceuticals in humans: B. Use of QSAR systems for early detection of drug-induced hepatobiliary and urinary tract toxicities","volume":"54","author":"Matthews","year":"2009","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.yrtph.2009.11.006_bib15","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/pds.1058","article-title":"The history of disproportionality measures (reporting odds ratio, proportional reporting rates) in spontaneous reporting of adverse drug reactions","volume":"14","author":"Moore","year":"2005","journal-title":"Pharmacoepidemeol. Drug Safety"},{"key":"10.1016\/j.yrtph.2009.11.006_bib16","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1385\/CT:3:4:311","article-title":"Emetine inhibits glycolysis in isolated, perfused rat hearts","volume":"3","author":"Pan","year":"2001","journal-title":"Cardiovasc. Toxicol."},{"key":"10.1016\/j.yrtph.2009.11.006_bib17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.yrtph.2008.12.009","article-title":"Identification of structure\u2013activity relationships for adverse effects of pharmaceuticals in humans A: use of FDA post market reports to create a database of hepatobiliary and urinary tract toxicities","volume":"54","author":"Ursem","year":"2009","journal-title":"Regul. Toxicol. Pharmacol."}],"container-title":["Regulatory Toxicology and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0273230009002281?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0273230009002281?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,24]],"date-time":"2019-05-24T01:11:03Z","timestamp":1558660263000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0273230009002281"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,4]]},"references-count":17,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,4]]}},"alternative-id":["S0273230009002281"],"URL":"https:\/\/doi.org\/10.1016\/j.yrtph.2009.11.006","relation":{},"ISSN":["0273-2300"],"issn-type":[{"value":"0273-2300","type":"print"}],"subject":[],"published":{"date-parts":[[2010,4]]}}}